Managing chronic kidney disease in diabetes patients with the latest chemical therapies

References

• Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180.
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
   PubMed Web of Science ®Google Scholar
• Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.
   PubMed Web of Science ®Google Scholar
• Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia. 2016;59:1616–1620.
   PubMedGoogle Scholar
• Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061–2068.
   PubMed Web of Science ®Google Scholar
• Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.
   PubMed Web of Science ®Google Scholar
• Nelson RG, Knowler WC, Pettitt DJ, et al. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care. 1995;18:182–187.
   PubMed Web of Science ®Google Scholar
• Hovind P, Rossing P, Tarnow L, et al. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2003;26:911–916.
   PubMed Web of Science ®Google Scholar
• Kharal M, Al-Hajjaj A, Al-Ammri M, et al. Meeting the American Diabetic Association standards of diabetic care. Saudi J Kidney Dis Transpl. 2010;21:678–685.
   PubMedGoogle Scholar
• Villar E, Remontet L, Labeeuw M, et al. Effects of age, gender and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol. 2007;18:2125–2134.
   PubMed Web of Science ®Google Scholar
• Duran-Salgado MB, Rubio-Guerra AF. Diabetic nephropathy and inflammation. World J Diabetes. 2014;5:393–398.
   PubMedGoogle Scholar
• Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med. 1981;70:603–612.
   PubMed Web of Science ®Google Scholar
• Katz A, Caramori ML, Sisson-Ross S, et al. An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int. 2002;61:2058–2066.
   PubMed Web of Science ®Google Scholar
• Kimmestiel P, Wilson C. Intercapillary lesions in the glomeruli of kidney. Am J Pathol. 1936;12:83–97.
   PubMedGoogle Scholar
• Lemley KV. Diabetes and chronic kidney disease: lessons from the Pima Indians. Pediatr Nephrol. 2008;23:1933–1940.
   PubMedGoogle Scholar
• Molitch ME, Steffes M, Sun W, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536–1543.
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen B, Mathiesen ER, Hegedns L, et al. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med. 1986;314:665–670.
   PubMed Web of Science ®Google Scholar
• Hajhosseiny R, Khavandi K, Jivraj N, et al. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs. 2014;23:511–522.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA). Standards of medical care in diabetes, 2008. Diabetes Care. 2008;31 Suppl 1:S12–S54.
   PubMed Web of Science ®Google Scholar
• Parving HH, Hommel E, Jensen BR, et al. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001;60:228–234.
   PubMed Web of Science ®Google Scholar
• Cha DR, Kang YS, Han SY, et al. Role of aldosterone in diabetic nephropathy. Nephrol Carlton. 2005;10:37–39.
   PubMedGoogle Scholar
• Sirgay HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol. 2008;93:817–824.
   PubMed Web of Science ®Google Scholar
• Remmuzzi G, Cattaneo D, Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol. 2008;19:1459–1462.
   PubMed Web of Science ®Google Scholar
• Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol. 2006;17:1362–1372.
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Matsumoto S, Aso Y, et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metabol. 2006;91:2214–2217.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Agarwal R, Chan JC, et al. Effect of finerenone in patients with diabetic Nephropathy (abstract). World Congress of Nephrology; 2015 Mar 13–17; Cape Town, South Africa.
   Google Scholar
• NCT02540993. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and diabetic kidney disease (FIDELIO-DKD). [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02540993
   Google Scholar
• NCT02545049. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease (FIGARO-DKD). [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02545049
   Google Scholar
• Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol. 2004;15:55–57.
   PubMed Web of Science ®Google Scholar
• Park IS, Kiyomoto H, Abboud SL, et al. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes. 1997;46:473–480.
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Kidney Int. 1998;54:1390–1391.
   PubMed Web of Science ®Google Scholar
• Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. J Hypertens. 2005;23:1931–1937.
   PubMed Web of Science ®Google Scholar
• Gambaro G, Kinalsaka I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the DINAS Randomized Trial. J Am Soc Nephrol. 2002;13:1615–1625.
   PubMed Web of Science ®Google Scholar
• Hanssen NM, Russell N, Cooper ME. Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. Expert Opin Pharmacother. 2015;16:1325–1333.
   PubMed Web of Science ®Google Scholar
• NCT00130208. Effect of sulodexide in early diabetic nephropathy. [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT00130208
   Google Scholar
• NCT01000545. The efficacy and safety study of sulodexide in filipino diabetic patients with chronic kidney disease (DEFINE). [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01000545
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3:101–108.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23:131–136.
   PubMed Web of Science ®Google Scholar
• NCT02156843. Pyridorin in diabetic nephropathy (PIONEER). [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02156843
   Google Scholar
• Danis RP, Sheetz MJ. Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother. 2009;10:2913–2925.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686–2690.
   PubMed Web of Science ®Google Scholar
• NCT00297401. Renal and peripheral hemodynamic function in patients with type 1 diabetes mellitus. [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT00297401
   Google Scholar
• Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2001;54:965–978.
   Google Scholar
• Hirata K, Kume S, Araki S, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380:44–49.
   PubMed Web of Science ®Google Scholar
• Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231:57–61.
   PubMed Web of Science ®Google Scholar
• Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2001;58:69–73.
   Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36:3460–3468.
   PubMed Web of Science ®Google Scholar
• NCT02467478. Linagliptin effect on CD34+ stem cells. [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02467478
   Google Scholar
• Yamout H, Bakris GL. Diabetic nephropathy: SGLT2 inhibitors might halt progression of diabetic nephropathy. Nat Rev Nephrol. 2013;12:583–584.
   Google Scholar
• Fioretto P, Zambon A, Rossato M, et al. SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care. 2016;39:165–171.
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–375.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al.. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
   PubMed Web of Science ®Google Scholar
• Dhaun N, Webb DJ, Kluth DC. Endothelin-1 and the kidney–beyond BP. Br J Pharmacol. 2012;167:720–731.
   PubMed Web of Science ®Google Scholar
• Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–535.
   PubMed Web of Science ®Google Scholar
• NCT01858532. Study of diabetic nephropathy with atrasentan (SONAR). [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01858532
   Google Scholar
• Ghorbani A, Omidvar B, Beladi-Mousavi SS, et al. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia. 2012;32:790–796.
   PubMed Web of Science ®Google Scholar
• Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs. 2010;19:275–283.
   PubMed Web of Science ®Google Scholar
• Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia. 2004;47:965–968.
   PubMed Web of Science ®Google Scholar
• NCT02689778. Effect of pirfenidone on glomerular filtration rate and albuminuria in patients with diabetic nephropathy. [cited 2016 Nov 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02689778
   Google Scholar
• Lambers Heerspink HJ, Holtkamp FA, Parving, H.H, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82:330–337.
   PubMed Web of Science ®Google Scholar
• Orth SR, Stöckmann A, Conradt C, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998;54:926–931.
   PubMed Web of Science ®Google Scholar
• Foreyt JP, Poston WS II. The challenge of diet, exercise and lifestyle modification in the management of the obese diabetic patient. Int J Obes Relat Metab Disord. 1999;23:5–11.
   PubMed Web of Science ®Google Scholar
• Thijssen S, Kitzler TM, Levin NW. Salt: its role in chronic kidney disease. J Ren Nutr. 2008;18:18–26.
   PubMed Web of Science ®Google Scholar